The CAR-T Therapy Shift: Redefining Second-Line Treatment Strategies in Multiple Myeloma : Episode 7
Strategic Choices in CAR T for Myeloma: Balancing Efficacy, Safety, and BCMA vs. GPRC5D Options
This video episode compares ide-cel and cilta-cel for patient selection, examining specific characteristics, efficacy and safety profiles, and their influence on treatment decisions across diverse patient groups.
Video content above is prompted by the following:
- How would you compare ide-cel and cilta-cel in terms of patient selection?
- Are there specific patient characteristics that might make you lean towards one CAR-T product over the other?
- How do the efficacy and safety profiles of these two products influence your decision-making for different patient groups?
Recent Videos
Related Content
